Pharmaceutical company Johnson & Johnson’s single-dose Covid-19 vaccine has received emergency-use authorisation in India, Union health minister Mansukh Mandaviya announced on Saturday.
“Now India has 5 EUA [approved for emergency use] vaccines,” the minister added. “This will further boost our nation’s collective fight against Covid-19.”
The government’s announcement came just two days after Johnson & Johnson applied for approval of its vaccine in India. The company will collaborate with Hyderabad-based Biological E Limited to launch the vaccine in India and other countries across the world.
In phase three clinical trials, the single-shot vaccine showed 85% efficacy in preventing severe disease, Johnson & Johnson said. The company added that its shot also offered protection against hospitalisation and death, starting 28 days after inoculation.
The single-dose vaccine has already been approved for use in several countries, including the United States, European Union members, Thailand and South Africa.
Apart from the dosage regimen, the Johnson & Johnson vaccine also differs from other shots in the way it creates resistance against the virus. The Pfizer-BioNTech and Moderna vaccines use new messenger RNA [Ribonucleic acid] technology to create an immune response, while this vaccine involves a more conventional approach, using a common cold virus to introduce coronavirus proteins into cells to trigger an immune response.
Also read:
How is the Johnson & Johnson vaccine different from the others? A virologist explains
Buy an annual Scroll Membership to support independent journalism and get special benefits.
Our journalism is for everyone. But you can get special privileges by buying an annual Scroll Membership. Sign up today!